Allegato a 836 2008

Allegato A
ESTENSIONE
SINTESI DELLE
INDICAZIONI GIÀ
INDICAZIONI
BIBLIOGRAFIA
COMPOSTO
AUTORIZZATE
SULLA BASE DI
A SOSTEGNO DELL’ESTENSIONE DELL’INDICAZIONE
NUOVE EVIDENZE
SCIENTIFICHE
ACICLOVIR
-Infezioni da Herpes
Lopez-Navidad A et al. Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. Scand J Infect Dis 1996; 28:185-187 -Infezioni da Herpes
Drago F et al. Epstein-Barr-virus-related primary cutaneous amyloidosis. Successful treatment with acyclovir and interferon-alpha. Br J Dermatol 1996; 134:170-174 -Osteogenesi
Braga V et al. Intravenous intermittent neridronate in the treatment of postmenopausal NERIDRONICO
imperfetta
-Morbo di Paget
Cascella T et al. Effects of neridronate treatment in elderly women with osteoporosis. J Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine -Metastasi ossee
Lavie F et al. Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: PAMIDRONICO
prevalentemente
development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 2007;74:346-352 -Mieloma multiplo
Toussirot E and Wendling D. Antiinflammatory treatment with bisphosphonates in -Ipercalcemia
ankylosing spondylitis. Curr Opin Rheumatol 2007;19:340-345 provocata da osteolisi
neoplastica
Grover R et al. Treatment of ankylosing spondylitis with pamidronate: an open label Maksymowych WP et al. A six-month randomized, controlled, double-blind, dose- resistenti a FANS e/o response comparison of intravenous pamidronate (60 mg versus 10 mg) in the non candidate a treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Toussirot E and Wendling D. Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies. Expert Opin Pharmacother 2005;6:35-43 Maksymowych WP et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001;28:144-155 ADALIMUMAB
-Artrite reumatoide
Fonder MA et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J -Artrite psoriasica
-Spondilite
Heffernan MP et al. Adalimumab treatment for pyoderma gangrenosum. Arch anchilosante
-Spondiloartriti
Pomerantz RG et al. Adalimumab for treatment of pyoderma gangrenosum. Br J -Psoriasi
-Malattia di Crohn
Ahmed MM et al. Treatment of refractory temporal arteritis with adalimumab. Clin Mushtaq B et al. Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye Van Laar JAM et al. Adalimumab: a new modality for Behçet’s disease? Ann Rheum Callejas-Rubio JL et al. Treatment of therapy-resistant sarcoidosis with adalimumab. Denys BG et al. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Heffernan MP and Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch -Arterite di Takayasu Tato F et al. Refractory Takayasu’s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 2005;24:304- Ortego-Centeno N et al. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2007;21:408-410 Mukhtyar C and Luqmani R. Current state of tumor necrosis factor [alpha] blockade in Wegener’s granulomatosis. Ann Rheum Dis 2005;64:31-36 Kozuch PL and Hanawer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008;14:354-377 Behm BW and Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;1:CD006893 Noe JD and Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008. Epub ahead of print Shepela C. The safety of biologic agents in the treatment of inflammatory bowel Coburn LA et al. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006;51:2045-2047 O’Donnell S and O’Morain C. Review article: use of antitumor necrosis factor therapy in inflammatory disease during pregnancy and conception. Aliment Pharmacol Ther 2008; 27:885-894 AMITRIPTILINA
-Depressione
Uçeyler N et al. A systematic review on the effectiveness of treatment with endogena
antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59:1279-1298 -Fase depressiva della
psicosi maniaco-
Ozerbil O et al. Comparison of the effects of two antidepressants on exercise depressiva
performance of the female patients with fibromyalgia. Clin Rheumatol 2006;25:495-497 -Profilassi
dell'emicrania e delle
cefalee croniche o
Goldenberg D et al. A randomized, double-blind crossover trial of fluoxetine and ricorrenti
amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-1859 AMLODIPINA
-Ipertensione
Sturgill MG and Seibold JR. Rational use of calcium-channel antagonists in Raynaud's arteriosa
phenomenon. Curr Opin Rheumatol 1998;10:584-588 -Angina pectoris
ANAKINRA
-Artrite reumatoide
Fitzgerald AA et al. Rapid response to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 2005;52:1794-1803 Vasques Godinho FM et al. Refractory adult onset Still’s disease successfully treated with anakinra. Ann Rheum Dis 2005;64:647-648 Kalliolias GD and Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008;17:349-359 Hawkins PN et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-612 Simon A et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Dierselhuis MP et al. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Haibel H et al. Open label trial of anakinra in active ankylosing spondylitis over 24 Tan AL et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63:1041-1045 Bennett AN et al. Sustained response to anakinra in ankylosing spondylitis. Schneider SW et al. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 2007;56:120-122 Gilson M et al. Treatment of Schnitzler's syndrome with anakinra. Clin Exp Rheumatol 2007;25:931 Wastiaux H et al. Schnitzler syndrome: a dramatic improvement with anakinra. J Eur Acad Dermatol Venereol 2008. Epub ahead of print ATORVASTATINA
-Ipercolesterolemia
Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr -Ipertrigliceridemia
-Iperlipidemie
Kuwana M et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006;54:1946-1951 Abou-Raya A et al. Statins as immunomodulators in systemic sclerosis. Ann N Y Acad Kotyla PJ Atorvastatin therapy improves endothelial-dependent vasodilatation in patients with systemic lupus erythematosus: an 8 week controlled trial. Rheumatology 2008;47:381-392 Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005;19:823-838 Jury EC and Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic disease? Lupus 2005;14:192-196 AZATIOPRINA
-Trapianti
Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel -Artrite reumatoide
vasculitis. Curr Opin Rheumatol 2007;19:17-24 -Malattie
Benenson E et al. High-dose azathioprine pulse therapy as a new treatment option in infiammatorie
patients with active Wegener's granulomatosis and lupus nephritis refractory or intestinali
intolerant to cyclophosphamide. Clin Rheumatol 2005;24:251-257 - Lupus eritematoso
sistemico
Little MA and Pusey CD. Glomerulonephritis due to antineutrophil cytoplasm -Dermatomiosite
antibody-associated vasculitis: an update on approaches to management. Nephrology -Polimiosite
-Epatite cronica
Lee JC et al. The long-term use of azathioprine in patients with psoriatic arthritis. J autoimmune
-Panarterite nodosa
Hoyles RK et al. A multicenter, prospective, randomized, double-blind, placebo- -Anemia emolitica
controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral autoimmune
azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum -Porpora
trombocitopenica
idiopatica
Hamuryudan V et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997;40:769-774 Yazici H et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med Gul A. Standard and novel therapeutic approaches to Behçet disease. Drugs Garini G et al. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis ant therapeutic strategies. Ann Ital Med Int 2005;20:71-80 Gross WL. New concepts in treatment protocols for severe systemic vasculitis. Curr Chen KR and Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Rogalski C and Sticherling M. Panarteritis cutanea benigna--an entity limited to the skin or cutaneous presentation of a systemic necrotizing vasculitis? Report of seven cases and review of the literature. Int J Dermatol 2007;46:817-821 Pipitone N and Salvarani C. Improving therapeutic options for patients with giant cell arteritis. Curr Opin Rheumatol 2008;20:17-22 Salvarani C et al. Diagnosis and management of polymyalgia rheumatica/giant cell arteritis. BioDrugs 1998;9:25-32 CICLOFOSFAMID
-Trattamento
de Groot K et al. Randomized trial of cyclophosphamide versus methotrexate for citostatico
induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-2469 Bosch X et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007;298:655-669 Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int Kameda H et al. Combination therapy with corticosteroids, cyclosporin A and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32:1719-1726 Bombardieri S et al. Cyclophosphamide in severe polymyositis. Lancet 1989;1:1138- Yamasaki Y et al. Intravenous cyclophosphamide therapy for progressive interstitial Boumpas DT et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-745 Mok CC et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:25-33 Seong SS et al. Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. Rheumatol Int 2008;28:453-458 Neuwelt CM et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41 Barile-Fabris L et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005;664:620-625 Medeiros MM et al. Healt-related quality of life in patients with systemic lupus erythematosus and its relationship with cyclophosphamide pulse therapy. Eur J Intern Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Expert Opin Tashkin DP et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Khanna D et al. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Langford CA et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of Marder W and McCune WJ. Advances in immunosuppressive therapy. Semin Respir Pagnoux C and Teixeira L. Wegener's granulomatosis. Presse Med 2007;36:860-874 Garini G et al. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis ant therapeutic strategies. Ann Ital Med Int 2005;20:71-80 Kayali Z et al. Treatment of hepatitis C cryoglobulinemia: mission and challenges. Curr Treat Opinion Gastroenterol 2006;9:497-507 Souayah N et al. Hepatitis C virus acute quadriparetic vasculitic neuropathy responsive to cyclophosphamide. Neurol Neurophysiol Neurosci 2006;18:5 Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297-350 Du LT et al. Value of "bolus" cyclophosphamide injections in Behçet's disease. Experience of 17 cases. Presse Med 1990;19:1355-1358 Melillo N et al. Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet's disease. Clin Rheumatol 2007;26:1365-1367 CICLOSPORINA
-Trapianti
Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol -Artrite reumatoide
-Uveite endogena
Fradin MS et al. Oral cyclosporine for severe chronic idiopathic urticaria and -Sindrome nefrosica
angioedema. J Am Acad Dermatol 1991;25:1065-1067 -Psoriasi
Gordon KB et al. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary -Dermatite atopica
Fraser AD. A randomised, double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyoclosporine in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-864 Sarzi Puttini P et al. Long term safety and efficacy of low dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 2002;21:234-238 Callen JP. Management of “refractory” skin disease in patients with lupus eritematosus. Best Pract Res Clin Rheumatol 2005;19:767-784 Wozniacka A et al. The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis. Clin Rheumatol 2007;26:1176-1179 Hilgard P et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Goto K et al. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporine A and NIM811. Biochem Biophys Res Commun 2006;343:879-884 CLONAZEPAM
-Epilessia
Colakoglu M et al. Effect of clonazepam on Raynaud’s phenomenon and fingertip ulcers in scleroderma. Ann Pharmacother 2007;41:1544-1547 CLOROCHINA
-Profilassi e
Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Pract trattamento della
-Amebiasi
Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol 2004;18:313-329 extraintestinale
-Artrite reumatoide
(poliartrite cronica),
Ang GC and Werth VP. Combination antimalarials in the treatment of cutaneous comprese le forme
dermatomyositis: a retrospective study. Arch Dermatol 2005;141:855-859 giovanili
- Lupus eritematoso
Wallace DJ. The use of chloroquine and hydroxychloroquine for non infectious discoide cronico
conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996;5:59- -Lupus eritematoso
sistemico
Roubey RA. Treatment of the antiphospholipid syndrome. Curr Opin Rheumatol Suarez IM et al. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus 1996;5:81-83 Sisó A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008;17:281-288 Tam LS et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000;27:2142-2145 COLCHICINA
Altenburg A et al. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007;21:1019-1026 Fontes V et al. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol 2002;129:1365-1369 Katz J et al. Prevention of recurrent aphthous stomatitis with colchicine: an open trial. J Carlson JA et al. Cutaneous vasculitis: diagnosis and management. Clin Dermatol Callen JP. Colchicine is effective in controlling chronic cutaneous leukocitoclastic vasculitis. J Am Acad Dermatol 1985;13:193-200 Hazen PG and Michel B. Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behçet’s syndrome. Arch -Febbre mediterranea Tufan A et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T familiare polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol Cerquaglia C et al. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Kosan C and Ozkan B. Once-daily use of colchicine in children with familial Mediterranean fever. Clin Pediatr 2004;43:605-608 Announ N and Guerne PA. Diagnosis and treatment of calcium pyrophosphate crystal- induced arthropathy. Z Rheumatol 2007;66:573-578 Lioté F and Ea HK. Recent developments in crystal-induced inflammation pathogenesis and management. Curr Rheumatol Rep 2007;9:343-350 Rosenthal AK and Ryan LM. Treatment of refractory crystal-associated arthritis. Rheum Dis Clin North Am 1995;21:151-161 COTRIMOSSA-
- Infezioni delle vie
respiratorie, renali,
sulfamethoxazole-trimethoprim monotherapy. Intern Med 2001;40:666-670 delle vie urinarie,
dell'apparato genitale
Stegeman CA et al. Trimethoprim-sulfamethoxazole (Co-trimoxazole) for the e dell'apparato
prevention of relapses of Wegener’s granulomatosis. Dutch Co-trimoxazole Wegener digerente
Study Group. N Eng J Med 1996;335:16-20 Reinhold-Keller E et al. Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. QJM 1996;89:15-23 DOXICICLINA
- Infezioni da germi
O’Dell JR et al. Treatment of early sieropositive rheumatoid arthritis: doxycycline plus sensibili alle
methotrexate versus methotrexate alone. Arthritis Rheum 2006;54:621-627 tetracicline
Gompels LL et al. Single-blind randomized trial of combination antibiotic therapy in rheumatoid arthritis. J Rheumatol 2006;33:224-227 Alarcon GS. Early rheumatoid arthritis: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy. Nat Clin Pract Rheumatol 2006;2:296- Webster G and Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Voils SA et al. Use of macrolides and tetracyclines for chronic inflammatory diseases. Ann Pharmacother 2005;39:86-94 Sapadin AN and Fleischemajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-265 DULOXETINA
- Depressione
Arnold LM et al. A double-blind, multicenter trial comparing duloxetine with placebo maggiore
in the treatment of fibromyalgia patients with or without major depressive disorder. -Dolore neuropatico
diabetico periferico
Arnold LM et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health 2007;16:1145-1156 Russell IJ et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:232-234 ETANERCEPT
-Artrite reumatoide
Sinico RA and Sabadini E. New insights in the treatment of ANCA-associated systemic -Psoriasi
vasculitis. G Ital Nefrol 2006;23:138-148 -Spondilite
Little MA et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental anchilosante
model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Huugen D et al. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol Drewe E and Powell RJ. Etanercept AL amyloidosis. Lancet 2001;358:761 Gottenberg JE et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-2024 Perry ME et al. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol Atzeni F et al. Successful treatment of resistant Behçet’s disease with etanercept. Clin Melikoglu M et al. Short-term of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105 Sfikakis PP et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology 2007;46:736-741 Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. J Tan AL et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Martínez-Taboada VM et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis Husni ME et al. Etanercept in the treatment of adult patients with Still’s disease. Fautrel B et al. Tumor necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-266 Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Iannone F et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Sprott H et al. Treatment of myositis with etanercept (Enbrel), a recombinant human fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology 2004;43:524- Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Wendling D et al. Anti TNF-alpha treatment of a refractory polymyositis. Rev Med Wagner AD et al. Sustained response to tumor necrosis factor alpha-bloking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-1968 Bosello S et al. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005;143:918-920 Lam GK et al. Efficacy and safety of etanercept in the treatment of scleroderma- associated joint disease. J Rheumatol 2007;34:1636-1637 Khanna D et al. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30:1864-1867 Utz JP et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-185 Tuchinda C and Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol 2006;5:538-540 FELODIPINA
-Ipertensione
Sturgill MG and Seibold JR. Rational use of calcium-channel antagonists in Raynaud's arteriosa
phenomenon. Curr Opin Rheumatol 1998;10:584-588 -Angina pectoris
Kallenberg CG et al. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 1991;40:313-315 FLUOXETINA
- Depressione
Ozerbil O et al. Comparison of the effects of two antidepressants on exercise maggiore
performance of the female patients with fibromyalgia. Clin Rheumatol 2006;25:495- -Disturbo ossessivo
compulsivo
Goldenberg D et al. A randomized, double-blind crossover trial of fluoxetine and -Bulimia nervosa
amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-1859 GABAPENTIN
-Epilessia
Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol 2008;20:246- -Dolore neuropatico
periferico
Arnold LM et al. Gabapentin in the treatment of fibromyalgia: a randomized, double- -Disturbo d’ansia
blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-1344 generalizzato
IDROSSI-
-Artrite reumatoide
Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Pract CLOROCHINA
-Lupus eritematoso
(discoide o sistemico)
Dawson LJ et al. Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology 2005;44:449-455 Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol 2004;18:313-329 Ang GC and Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005;141:855-859 Wallace DJ. The use of chloroquine and hydroxychloroquine for non infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus 1996;5:59- Vuolteenaho K et al. Aureothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage. Scand J Rheumatol Bryant LR et al. Hydroxychloroquine in the treatment of erosive osteoarthritis. J Yoon KH. Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid syndrome. J Rheumatol 2002;29:1574-1575 Espinola RG et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;3:518-522 Roubey RA. Treatment of the antiphospholipid syndrome. Curr Opin Rheumatol Tsakonas E et al. A long term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian hydroxychloroquine Sisó A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 2008;17:281-288 Ruiz-Irastorza G and Khamashta M. Hydroxychloroquine: the cornerstone of lupus Levy RA. Hydroxychloroquine (HCQ) in lupus prengnancy: double blind and placebo Costedoat-Chalumeau N et al. Safety of hydroxychloroquine in pregnant patients with connettive tissues diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-3211 Tam LS et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000;27:2142-2145 Tandon VR et al. Pregnancy and rheumatoid arthritis. Indian Med Sci 2006;60:334-344 Ostensen M and Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 1998;19:389-410 Vroom F et al. Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006;29:845-863 ILOPROST
-Tromboangioite
Hachulla E et al. Iloprost for the treatment of systemic sclerosis. Presse Med obliterante (morbo di
Bürger) in stadio
avanzato
Launay D et al. Pulmonary arterial hypertension and systemic sclerosis. Presse Med -Ischemia arteriosa
cronica grave degli
arti inferiori
Caramaschi P et al. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol Int 2006;27:203- -Fenomeno di
Raynaud secondario
a sclerodermia
-Terapia sostitutiva
Dalakas MC. The role of high-dose immunoglobulins intravenous in the treatment of GLOBULINE
-Porpora
dermatomyositis. Int Immunopharmacol 2006;6:550-556 trombocitopenica
idiopatica
Al-Mayouf SM et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000;27:2498-2503 -Sindrome di Guillain
Kuwano Y et al. Successful treatment of dermatomyositis with high-dose intravenous -Poliradicolo-
immunoglobulin. Acta Derm Venereol 2006;86:158-159 neuropatia cronica
-Neuropatia motoria
Sadayama T et al. Low-dose intravenous immunoglobulin therapy for intractable multifocale
dermatomyositis skin lesion. J Dermatol 1999;26:457-459 -Sindrome di
Kawasaki
Williams L et al. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. Obstet Gynecol 2007;109:561-563 -Trapianto allogenico
di midollo osseo
Muscat C et al. Long term treatment of rheumatoid arthritis with high doses of -Infezioni
intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann -Malattia da
trapianto verso
l’ospite
Pap T et al. Effects of intravenous immunoglobulins on disease activity and cytokine plasma levels in rheumatoid arthritis. Scand J Rheumatol 1998;27:157-159 Maeda H et al. Successful treatment of ‘malignant rheumatoid arthritis’ in Japan with pooled intravenous immunoglobulin. Rheumatology 2001;40:955-956 Sherer Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 2006;5:153-155 Zandman-Goddard G et al. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005;29:219-228 Sherer Y et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008;10:55-57 Milstone AM et al. Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol Lazurova I et al. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clin Rheumatol 2007;26:2145-2147 Rauova L et al. High-dose intravenous immunoglobulins for lupus nephritis – a salvage Boletis JN et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354:569-570 Monova D et al. Intravenous immunoglobulin G in the treatment of patients with chronic glomerulonephritis: clinical experience lasting 15 years. Nephron 2002;90:262- Gordon C and Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus Perricone R et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology Gordon C and Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus Triolo G et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003;48:728-731 Konova E. Intravenous immunoglobulin therapy in antiphospholipid syndrome. Clin Hsiao GR et al. Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J Clin Rheumatol 2001;7:336-339 Horn HC et al. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus 2004;13:478-480 De Vita S et al. High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience. Clin Exp Rheumatol 1996;14:85-92 Shoenfeld Y et al. IV Ig therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005;38:123-137 Miniati I el al. Pregnancy in systemic sclerosis. Rheumatology 2008;47:16-18 Nacci F et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007;66:977-979 Levy Y et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin. A preliminary report. Clin Rheumatol 2000;19:207-211 INFLIXIMAB
-Artrite reumatoide
Sinico RA and Sabadini E. New insights in the treatment of ANCA-associated systemic -Artrite psoriasica
vasculitis. G Ital Nefrol 2006;23:138-148 -Spondilite
Little MA et al. Therapeutic effect of anti-TNF-alpha antibodies in an experimental anchilosante
model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc -Colite ulcerosa
-Malattia di Crohn
Huugen D et al. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated -Psoriasi
vasculitis: clinical and experimental considerations. Clin J Am Soc Nephrol -Arterite di Takayasu Hoffman GS et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50:2296-2304 Karageorgaki ZT et al. Infliximab in Takayasu arteritis: a safe alternative? Clin Tanaka F et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006;45:313-316 Niccoli L et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 2007;46:1161-1164 Abu El-Asrar AM et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int Ophtalmol 2005;26:83-92 Lanthier N et al. Infliximab in the treatment of posterior uveitis in Behçet’s disease. Long term follow up in four patients. Presse Med 2005;34:916-918 Ribi C et al. Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro- impegno neurologico Behçet disease. J Neurol Neurosurg Psychiatry 2005;76:1733-1735 Sarwar H et al. Successful treatment of long-standing neuro-Behçet's disease with López Rodríguez M et al. Biological therapy with anti-TNF antibodies. Extending the spectrum of its indications? Rev Clin Esp 2007;207:448-450 Gul A. Standard and novel therapeutic approaches to Behçet's disease. Drugs Sfikakis PP et al. Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology 2007;46:736-741 Takamoto M et al. Long-term infliximab treatment for Behçet's disease. Jpn J Lee JH et al. Remission of intestinal Behçet’s disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Korean J Intern Med 2007;22:24-27 Torrente SV et al. Amaurosis in patients with giant cell arthritis: treatment with anti- tumor necrosis factor alpha. Intern Med J 2007;37:1280-1291 Uthman I et al. Infliximab as a monotherapy in giant cell arteritis. Clin Rheumatol Bacon PA. Should infliximab be used to help maintain glucocorticosteroid-induced remission in patients with giant cell arteritis? Nat Clin Pract Rheumatol 2007;3:600- Brooklyn TN et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized double blind, placebo controlled trial. Gut 2006;55:505-509 Reguirai Z and Grange F. The role of anti-tumor necrosis factor-alpha therapy in pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Reichrath J et al. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Kraetsch HG et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis 2001;60:55-57 Fautrel B et al. Tumor necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 2005;64:262-266 Cavagna L et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001;19:329-332 Elkayam O et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum Gottemberg JE et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidisis secondary to inflammatory arthritis: a follow-up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-2024 Ortiz-Santamaria V et al. Treatment of secondary amyloidosis with infliximab. Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Korkmaz C et al. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumor necrosis factor-alpha. Rheumatology 2004;43:937- Hengstman GJ et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59:159-163 Efthimiou P et al. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Wendling D et al. Anti TNF-alpha treatment of a refractory polymyositis. Rev Med Wagner AD et al. Sustained response to tumor necrosis factor alpha-bloking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-1968 Olivieri I et al. Pharmacological management of SAPHO syndrome. Expert Opin Bosello S et al. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005;143:918-920 Antoniou KM et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007;25:23-28 ISRADIPINA
-Ipertensione
Sturgill MG and Seibold JR. Rational use of calcium channel antagonists in Raynaud's arteriosa
phenomenon. Curr Opin Rheumatol 1998;10:584-588 -Angina pectoris
La Civita L et al. Effect of isradipine on endothelin-1 plasma concentrations in patients with Raynaud's phenomenon. Ann Rheum Dis 1996;55:331-332 Leppert J et al. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Cardiovasc Drugs Ther 1989;3:397-401 LEFLUNOMIDE
-Artrite reumatoide
-Sclerodermia: artrite Sebastiani M et al. Successful treatment with leflunomide of arthritis in systemic -Artrite psoriasica
sclerosis patients. Rheumatology 2006;45:1175-1176 Metzler C et al. Maintenance of remission with leflunomide in Wegener’s granulomatosis. Rheumatology 2004;43:315-332 Jayne D. Leflunomide versus methotrexate in Wegener's granulomatosis. Boswell JS and Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol 2008;58:403-406 METOTREXATO
Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel -Artrite reumatoide
vasculitis. Curr Opin Rheumatol 2007;19:17-24 -Artrite psoriasica
Bosch X et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007;298:655-669 Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int Little MA and Pusey CD. Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management. Nephrology Bohan A et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-286 Vencovsky J et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95-102 Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 2006; 16: 223-226 Toussirot E et al. Late-onset ankylosing spondylitis and related spondyloarthropathies: clinical and radiological characteristics and pharmacological treatment options. Drugs Kataria RK and Brent LH. Spondyloarthropathies. Am Fam Physician 2004; 69:2853- Queiro R De Dios Jr. Successful treatment with low-dose weekly methotrexate in a case of undifferentiated spondyloarthropathy coexisting with cutaneous polyarteritis Krishna Sumanth M et al. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol 2007;46:218-223 Van den Hoogen FH et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-372 Blank N et al. The role of DMARDs in systemic sclerosis therapy. Rheumatology Wong JM and Esdaile JM. Methotrexate in systemic lupus erythematosus. Lupus Sanchez Y and Carvallo A. Methotrexate use in patients with systemic lupus erythematosus. Rev Med Chil 2004;132:195-201 Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001;10:162- Kuhn A et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002;46:600-603 Soubrier M et al. Polymyalgia rheumatica: diagnosis and treatment. Joint Bone Spine Pipitone N et al. Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheumatol 2005;19:277-292 Caporali R et al. Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500 Lin P and Liang G. Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 2006;12:282-286 Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Davatchi F et al. High dose methotrexate for ocular lesions of Behçet's disease. Preliminary short-term results. Adv Exp Med Biol 2003;528:579-584 Kikuchi H et al. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003;528:575-578 Hirohata S et al. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 1998;159:181-185 Kaklamani VG and Kaklamanis PG. Treatment of Behçet's disease-an update. Semin Pipitone N and Salvarani C. Improving therapeutic options for patients with giant cell arteritis. Curr Opin Rheumatol 2008;20:17-22 Rimar D et al. Giant cell arteritis: the methotrexate debate revisited. J Rheumatol Mahr AD et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789-2797 Pouplin S et al. Treatment of eosinophilic fascitis with methotrexate. J Rheumatol Janzen L et al. Response to methotrexate in a patient with idiopathic eosinophilic fascitis, morphea, IgM hypergammaglobulinemia, and renal involvement. J Rheumatol Bischoff L and Derk CT. Eosinophilic fascitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol Shimizu T et al. A case of refractory Wegener's granulomatosis successfully treated with high-dose methotrexate. Nihon Kokyuki Gakkai Zasshi 2006;44:853-857 Specks U. Methotrexate for Wegener's granulomatosis: what is the evidence? Arthritis Langford CA et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate Carlson JA et al. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006;24:414-429 MICOFENOLATO
-Rigetto acuto
Drosos AA. Newer immunosuppressives drugs: their potential role in rheumatoid MOFETILE
arthritis therapy. Drugs 2002;62:891-907 Grundmann-Kollman M et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000;42: 835-837 Shahar E et al. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients non responding to antihistamines and/or corticosteroids. Int J Dermatol 2006;45:1224-1227 Iaccarino L et al. Mycophenolate mofetil: what in its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007;6:190-195 Henry SD et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon alpha. Gastroenterology 2006;131:1452- Russell JP and Weenig RH. Primary cutaneous small vessel vasculitis. Curr Treat Options Cardiovasc Med 2004;6:139-149 MICOFENOLATO
-Rigetto acuto
Mak SK et al. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology 2008;13:331-336 Kitiyacara C et al. Treatment of lupus nephritis and primary glomerulonephritis with enteric-coated mycophenolate sodium. Clin Nephrol 2008; 69:90-101 -Sindrome di Sjogren Willeke P et al. Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial. Arthritis Res Ther 2007;9:R115 Sanchez Fructuoso A et al. Better mycophenolic acid 12-hour through level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. Transplant Proc 2007;39:2194-2196 Bolin P et al. Improvement in 3 month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric coated mycophenolate sodium in renal transplant patients. Transplantation 2007; 84:1443-1451 Chan L et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric coated mycophenolate sodium. Transplantation 2007;81:1290-1297 NICARDIPINA
-Ipertensione
Sturgill MG and Seibold JR. Rational use of calcium channel antagonists in Raynaud's arteriosa
phenomenon. Curr Opin Rheumatol 1998;10:584-588 -Angina pectoris
No authors listed. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France. Am Heart J 1991;122:352-355 NIFEDIPINA
-Ipertensione
Sturgill MG and Seibold JR. Rational use of calcium channel antagonists in Raynaud's arteriosa
phenomenon. Curr Opin Rheumatol 1998;10:584-588 -Angina pectoris
Belch JJ and Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs 1996;52:682- 695 Maricq HR et al. Evaluation of treatment efficacy of Raynaud’s phenomenon by digital blood response to cooling. Vasc Med 2000;5:135-140 NISOLDIPINA
-Ipertensione
Gjørup T et al. Controlled double blind trial of nisoldipine in the treatment of arteriosa
idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 1986;31:387-389 -Angina pectoris
PAROXETINA
-Depressione
Patkar AA et al. A randomized, controlled trial of controlled release paroxetine in maggiore
-Disturbo ossessivo
compulsivo
-Disturbo da attacchi
di panico con o senza
agorafobia
- Disturbo d’ansia
sociale/fobia sociale
-Disturbo d’ansia
generalizzata
-Disturbo da stress
post-traumatico
PIMECROLIMUS
-Dermatite atopica
Luger T and Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology 2007;215:45-54 Tzellos TG and Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008;64:337-341 Wollina U and Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008;22:1-6 PRAVASTATINA
-Ipercolesterolemia
Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol -Ipertrigliceridemia
-Iperlipidemie
Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr Furukawa S et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 2006;65:1118-1120 Costenbader KH. A pravastatin dose-escalation study in systemic lupus erythematosus Rheumatol Int 2007;27:1071-1077 Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 2005;19:823-838 PREGABALIN
-Epilessia
Mease PJ et al. A randomized, double-blind, placebo-controlled, phase III trial of -Dolore neuropatico
pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502- periferico e centrale
-Disturbo d’ansia
Owen RT. Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia generalizzato
syndrome. Drugs Today 2007;43:857-863 Arnold LM et al. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007; 8:633-638 RITUXIMAB
-Linfomi
Keogh KA et al. Induction of remission by B lymphocyte depletion in eleven patients -Artrite reumatoide
with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Hinze CH and Colbert RA. B-cell depletion in Wegener's granulomatosis. Clin Rev Aouba A et al. Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. Clin Rev Allergy Immunol 2008;34:65-73 Keogh KA et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-187 George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664-1672 Niewold TB et al. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol 2006;33:1194-1196 Braendstrup P et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-280 Roccatello D et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008;34:111-117 Bryce AH et al. Response to rituximab in patients with type II cryoglobulinemia. Clin Zaja F et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood Kamar N et al. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int Bruchfeld A et al. Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia-anti-viral therapy vs rituximab. Rheumatology 2006;45:783-784 Quartuccio L et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology Saadoun D et al. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20:23-28 Dore MP et al. Cryoglobulinemia related to hepatitis C virus infection. Dig Dis Sci Pekow J and Chung RT. Treatment of type II cryoglobulinemia associated with hepatitis C with rituximab. J Clin Gastroenterol 2006;40:450 Finsterer J. Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Cai FZ et al. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006;33:1197-1198 Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J Ramos-Casals M and Font J. Extrahepatic manifestations in patients with chronic epatitis C virus infection. Curr Opin Rheumatol 2005;17:447-455 Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol Gottenberg JE et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913–920 Galarza C et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allerg Immunol 2008;34: 124-128 Liossis SN and Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin Immunol 2008;127:280-285 Noss EH et al. Rituximab as a therapy for refractory polymyositis and dermatomyositis. Lambotte O et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol Brulhart L et al. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Touma Z et al. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Joint Bone Spine 2008;75:334-337 Dinh HV et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56:148-153 Thatayatikom A and White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006;5:18-24 Lindholm C et al. Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol Eisenberg R. Targeting B cells in SLE: the experience with rituximab treatment (anti- CD20). Endocr Metab Immune Disord Drug Targets 2006;6:345-350 Looney RJ et al. New therapies for systemic lupus erythematosus: cellular targets. Mikiko T et al. Efficacy of rituximab for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66;470-475 Armstrong DJ et al. SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Rheumatol Int 2006;26: 771-772 Rojas-Garcia R et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 2003;61:1814-1816 Anandacoomarasamy A et al. ‘Cure’ of life threatening antiphospholipid syndrome with rituximab. Intern Med J 2006;36:474-475 Rubenstein E et al. Rituximab treatment for resistant antiphospholipid syndrome. J Merrill JT. Rituximab in antiphospholipid syndrome. Curr Rheumatol Rep 2003;5:381- D’Arena G et al. Monoclonal antibodies: new therapeutic agents for autoimmune haemolytic anemia? Endocr Metab Immune Disord Drug Targets 2008;8:62-68 Martinez-Velasco E et al. The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia. Farm Hosp 2007;31:124-127 Wang L et al. Anti-CD20 monoclonal antibody for the treatment of refractory autoimmune haemolytic anemia. Zhongguo Shi Yan Ye Xue Za Zhi 2007;15:425-428 SERTRALINA
-Depressione
Gonzalez-Viejo MA et al. A comparative study of fibromyalgia treatment: -Depressione
ultrasonography and physiotherapy versus sertraline treatment. Ann Readapt Med Phys associata ad ansia
-Disturbo ossessivo-
Ozgocmen S et al. Antioxidant status, lipid peroxidation and nitric oxide in compulsivo
fibromyalgia: etiologic and therapeutic concerns. Rheumatol Int 2006;26:598-603 -Disturbo da attacchi
di panico con o senza
agorafobia
SILDENAFIL
-Disfunzione erettile
-Sclerodermia: ulcere Chung L Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Gore J and Silver R. Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005;64:1387 Colglazier CL et al. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005;32:2440-2442 Pope JE. The diagnosis and treatment of Raynaud’s phenomenon: a pratical approach. Jiménez López-Guarch C et al. Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results. Rev Esp Cardiol 2004;57:946-951 Ruiz MJ et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2- year experience. J Heart Lung Transplant 2006;25:1353-1357 Singh TP et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Badesch DB et al. Sildenafil for pulmonary hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-2422 SIMVASTATINA
-Iperolesterolemia
Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr -Ipertrigliceridemia
-Iperlipidemie
Del Papa N et al. Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 2008;35:1323-1328 SULFASALAZINA
-Colite ulcerosa
Marguerie L et al. Use of disease-modifying antirheumatic drugs in patients with -Malattia di Crohn
psoriatic arthritis. Join Bone Spine 2002;69:275-281 -Artrite reumatoide
Soriano ER and McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-1430 Akkoc N et al. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol 2006;20:539-557 Chen J and Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006;33:722-731 Vroom F et al. Disease-modifying antirheumatic drugs in pregnancy: current status and implication for the future. Drug Saf 2006:29:845-863 Ostensen M and Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf 1998;19:389-410 Ostensen M. Optimization of antirheumatic drug treatment in pregnancy Clin Pharmacokinet 1994;27:486-503 TACROLIMUS
Uso sistemico:
Lafyatis R. Targeting fibrosis in systemic sclerosis. Endocr Metab Immune Disord -Profilassi del rigetto
del trapianto
allogenico di rene o di
Asano Y et al. Differential effects of the immunosuppressant FK-506 on human alpha2 (I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts. Arthritis Rheum 2005;52:1237-1247 - Trattamento del
rigetto allogenico
resistente al
Morton SJ and Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical trattamento con altri
setting for scleroderma. Rheumatology 2000;39:865-869 immunosoppressori
Tzellos TG and Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of Uso topico:
-Dermatite atopica
cutaneous lupus erythematosus: an evidence based evaluation. Eur J Cin Pharmacol Wollina U and Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008;22:1-6 Sugano M et al. Successful treatment with topical tacrolimus in four cases of discoid lupus erythematosus. J Dermatol 2006;33:887-891 Peyrot I et al. Topical tacrolimus and resistant skin lesions of dermatomyositis. Rev Ytterberg SR. Treatment of refractory polymiositis and dermatomyositis. Curr Holar CB et al. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004;15:35-39 Kessel A et al. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005;52:145-148 Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005;50:297-350 Sakane T et al. A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions. Ryumachi 1995;35:802-813 Koga T et al. Pulmonary infiltrates recovered by FK506 in a patient with Behçet's disease. Chest 1993;104:309-311 UROCHINASI
-Occlusioni venose o
Margheri F et al. Domain 1 of the urokinase-tipe plasminogen activator receptor is arteriose acute di
required for its morphologic and functional beta 2 integrin-mediated connection with origine trombotica o
actin cytoskeleton in human microvascular endothelial cells: failure of association in embolica
systemic sclerosis endothelial cells. Arthritis Rheum 2006;54:3926-3938 D’Alessio S et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004;50:3275-3285 Bazzichi L et al. Clinical improvement in systemic sclerosis resulting from urokinase therapy explained by light and electron microscopy skin examination. Scand J Rheumatol 2003;32:264-267 VALGANCICLOVI
-Infezioni da Herpes
Lopez-Navidad A et al. Epstein-Barr virus infection associated with interstitial nephritis and chronic fatigue. Scand J Infect Dis 1996;28:185-187 -Infezioni da Herpes
Kogelnik AM et al. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol 2006;37:33-38

Source: http://www.alessandrolupolionlus.org/download/pubblicazioni/All.A%20-%20DGRT%20836-2008.pdf